Tenax Therapeutics Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $10.9 million, compared to a net loss of $3.6 million in the same period in 2024. The company's General and Administrative (G&A) expenses increased due to a $3.6 million rise in non-cash stock-based compensation expense, attributed to option grants from December 2024 and May 2025. Additionally, salaries, performance-based compensation, legal, and professional fees experienced an uptick. The research and development (R&D) expenses for the second quarter of 2025 reached $6.1 million, up from $2.3 million in 2024. This increase was largely due to heightened clinical development costs for the Phase 3 LEVEL study and the initiation of the LEVEL-2 study, alongside an increase in R&D personnel costs. Tenax Therapeutics has made significant strides in its corporate operations, with plans to initiate the second Phase 3 study, LEVEL-2, this year. The company has expanded its operations team to oversee the LEVEL program, adding new leadership in Clinical Operations, Data Management, Pharmacovigilance, and Quality Assurance. As of June 30, 2025, Tenax holds $105.5 million in cash and cash equivalents, which is expected to fund the company through 2027.